10:46 AM EDT, 05/01/2024 (MT Newswires) -- Editas Medicine ( EDIT ) said Wednesday that it has extended its collaboration with Bristol-Myers Squibb ( BMY ) in autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases for another two years.

The company said Bristol-Myers has opted for 13 different programs across 11 gene targets to date as part of the collaboration that can be extended for up to an additional two years.

Editas shares were up more than 4% in recent trading.

Price: 5.45, Change: +0.24, Percent Change: +4.51